Cardiac Power Output in Cardiogenic Shock Patients

Recruiting Early Phase 1 Interventional Study
Heart Failure Cardiogenic Shock
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Early Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
5 (estimated)
Sponsor
University of Chicago · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The main purpose of this study is to determine whether differences in myocardial reserve predict clinical outcomes for heart failure patients.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. LVEF ≤ 40% 2. Referred for RHC for: 1. Evaluation for advanced heart failure therapies, including LVAD, OHT, temporary or long-term inotrope therapy, or counter-pulsation (temporary or long-term with NuPulse device OR 2. Accurate assessment of invasive hemodynamics due…
Contacts

David Onsager, MD

7737021000

donsager1@uchgicagomedicine.org

CONTACT

Daniel Rodgers

drodgers3@uchgicagomedicine.org

CONTACT